2. Search Result
Search Result
Results for "

enpp-1

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

3

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-RS04387
    ENPP1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    ENPP1 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    ENPP1 Human Pre-designed siRNA Set A
    ENPP1 Human Pre-designed siRNA Set A
  • HY-153334
    Enpp-1-IN-15

    		Phosphodiesterase (PDE) Others
    Enpp-1-IN-15 (Compound 88a) is an Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp-1) Inhibitor, with a Ki value of 0.00586 nM [1].
    <em>Enpp-1</em>-IN-15
  • HY-145062
    Enpp-1-IN-4

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-4 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). Enpp-1-IN-4 has the potential for the research of cancer diseases (extracted from patent WO2019177971A1, compound 1) [1].
    <em>Enpp-1</em>-IN-4
  • HY-145064
    Enpp-1-IN-6

    		Phosphodiesterase (PDE) Infection Cancer
    Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-6 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) [1].
    <em>Enpp-1</em>-IN-6
  • HY-145065
    Enpp-1-IN-7

    		Phosphodiesterase (PDE) Infection Cancer
    Enpp-1-IN-7 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-7 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) [1].
    <em>Enpp-1</em>-IN-7
  • HY-145069
    Enpp-1-IN-8

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-8 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-8 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) [1].
    <em>Enpp-1</em>-IN-8
  • HY-145070
    Enpp-1-IN-9

    		Phosphodiesterase (PDE) Infection Cancer
    Enpp-1-IN-9 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-9 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) [1].
    <em>Enpp-1</em>-IN-9
  • HY-145063
    Enpp-1-IN-5

    		Phosphodiesterase (PDE) Infection Inflammation/Immunology Cancer
    Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-5 has the potential for the research of cancer and infectious diseases (extracted from patent WO2019046778A1/WO2021203772A1, compound 1) [1] .
    <em>Enpp-1</em>-IN-5
  • HY-147389
    Enpp-1-IN-14

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-14 (Compound 015) is a potent Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) inhibitor with an IC50 value of 32.38 nM for recombinant human ENPP-1. Enpp-1-IN-14 has anti-tumor activity [1].
    <em>Enpp-1</em>-IN-14
  • HY-153335
    Enpp-1-IN-16

    		Phosphodiesterase (PDE) Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders [1].
    <em>Enpp-1</em>-IN-16
  • HY-163343
    Enpp-1-IN-20

    		Phosphodiesterase (PDE) STING Cancer
    Enpp-1-IN-20 (Compound 31) is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor, with an IC50 of 0.09 nM. Enpp-1-IN-20 has strongest inhibitory activity in the cell-based assay, with an IC50 of 8.8 nM. Enpp-1-IN-20 has significant potency in both ENPP1 inhibition and STING pathway stimulation in vitro. Enpp-1-IN-20 can be used for the research of cancer [1].
    <em>Enpp-1</em>-IN-20
  • HY-129490
    Enpp-1-IN-1
    2 Publications Verification

    		 Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-1 is a Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitor extracted from patent WO2019046778, Example 55 [1].
    <em>Enpp-1</em>-IN-<em>1</em>
  • HY-155457
    Enpp-1-IN-19

    		Phosphodiesterase (PDE) STING Cancer
    Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC50=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence [1].
    <em>Enpp-1</em>-IN-19
  • HY-143256
    Enpp-1-IN-12

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-12 (compound 43) is a potent and orally active ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor, with a Ki of 41 nM. Enpp-1-IN-12 exhibits anti-tumor activity [1].
    <em>Enpp-1</em>-IN-12
  • HY-139362
    Enpp-1-IN-2

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-2 (Compound C) is a potent ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) inhibitor with IC50 values of 0.26, 0.48 and 2.0 μM evaluated by means of TG-mAMP, pNP-TMP, and ATP assays, respectively. TG (Tokyo Green)-mAMP: a newly synthesized sensitive ENPP1 fluorescence probe [1].
    <em>Enpp-1</em>-IN-2
  • HY-143254
    Enpp-1-IN-10

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-10 (compound 1) is a potent Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor with an Ki value of 3.866 μM. Enpp-1-IN-10 can be used for researching anticancer [1].
    <em>Enpp-1</em>-IN-10
  • HY-147998
    Enpp-1-IN-13

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-13 (Compound 1a) is an ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) inhibitor with IC50 values of 1.29 μM and 20.2 μM against ENPP1 and ENPP3, respectively. Enpp-1-IN-13 shows anticancer activity [1].
    <em>Enpp-1</em>-IN-13
  • HY-143255
    Enpp-1-IN-11

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-11 (compound 23) is a potent Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor with an Ki value of 45 nM. Enpp-1-IN-11 exhibits low clearance in human and mouse liver microsomes, good plasma stability in human and mouse plasma. Enpp-1-IN-11 can be used for researching anticancer [1].
    <em>Enpp-1</em>-IN-11
  • HY-153398
    Enpp-1-IN-17

    		Phosphodiesterase (PDE) Infection Cancer
    Enpp-1-IN-17 (example 274) is a potent ENPP1 inhibitor, with the inhibition constants (Ki values) toward cGAMP and ATP hydrolysis of 100 nM-1 μM and > 1 μM, respectively. The selectivity ratio for inhibition of cGAMP hydrolysis versus ATP hydrolysis is >6.4 [1].
    <em>Enpp-1</em>-IN-17
  • HY-157522
    NCI-14465

    		Phosphodiesterase (PDE) Cancer
    NCI-14465 is an ectonucleotide pyrophosphatase/phosphodiesterase (ENPP1) inhibitor with an IC 50 of 26.4 μM. NCI-14465 can be used in cancer research [1].
    NCI-14465

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: